ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Takayasu.s arteritis"

  • Abstract Number: 0698 • ACR Convergence 2024

    Association of Systemic Sclerosis with ANCA-Associated Vasculitis and Large Vessel Vasculitis: Impact of Pulmonary Arterial Hypertension

    Brett Dinner1, Ahmed Abdelmaksoud2, Ann Igoe3, Taylor Viggiano4 and Vivek Nagaraja5, 1Creighton University, Paradise Valley, AZ, 2University of California, Riverside, Riverside, CA, 3Flow, Tempe, AZ, 4Mayo Clinic, Phoenix, 5Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder with excessive fibrosis and vasculopathy. While typically non-inflammatory, frank vasculitis can complicate SSc. Concomitant SSc with ANCA-associated…
  • Abstract Number: 2628 • ACR Convergence 2024

    Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study

    James Bistolarides1, Vidya Sivaraman2, Else Bosman3, Linda Wagner-Weiner4, Kimberly Morishita5, James Nocton1, Melodee Liegl1, Amy Pan1 and David Cabral6, and PedVas Investigators Network, 1Medical College of Wisconsin, Milwaukee, WI, 2Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 3UBC, Vancouver, BC, Canada, 4University of Chicago, Chicago, IL, 5University of British Columbia - Vancouver, Vancouver, BC, Canada, 6BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…
  • Abstract Number: 0746 • ACR Convergence 2024

    Single-cell RNA-Seq Analysis Reveals Distinct Compositional Characterizations and Transcriptomic Profiles of Macrophages in Takayasu’s Arteritis

    Lihong du1, Chenglong Fang2, shang Gao3, zuoguan Chen3 and Yongjun Li3, 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, 2Department of Rheumatology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, China (People's Republic), 3Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology, Beijing, China

    Background/Purpose: Macrophages play key roles in the pathogenesis of various inflammatory vascular diseases, such as Takayasu’s arteritis (TAK) and atherosclerosis. However, limited data on the…
  • Abstract Number: 1568 • ACR Convergence 2023

    Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis

    Sema Kaymaz-Tahra1, Ozun Bayindir Tsechelidis2, Burak Ince3, Ozlem Ozdemir Isik4, Muhammet Emin Kutu5, Ozlem Karakas6, Tuba Demirci Yildirim7, Zeliha Ademoglu8, Elif Durak Ediboglu9, Burcu Ceren Ekti Uludogan10, Can Ilgin11, Sule Yasar Bilge12, Timucin Kasifoğlu12, Servet Akar9, Hakan Emmungil8, Fatos Onen13, Ahmet Omma6, Nilufer Alpay Kanitez14, Ayten Yazici4, Ayse Cefle15, Murat Inanç16, Kenan Aksu17, Gökhan Keser17, Haner Direskeneli18 and fatma Alibaz-Öner19, 1Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, 2Ottawa University, Ottawa, ON, Canada, 3Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 4Kocaeli University Faculty of Medicine, Kocaeli, Turkey, 5Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 6Ankara City Hospital, Ankara, Turkey, 7Dokuz Eylul University, Izmir, Turkey, 8Trakya University Faculty of Medicine, Edirne, Turkey, 9Katip Celebi University Faculty of Medicine, Izmir, Turkey, 10Osmangazi University Faculty of Medicine, Eskişehir, Turkey, 11Marmara University Faculty of Medicine, Istanbul, Turkey, 12Division of Rheumatology, Medical School, Osmangazi University, Eskişehir, Turkey, 13Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 14Koc University Faculty of Medicine, Istanbul, Turkey, 15Division of Rheumatology, Medical School, Kocaeli University, Kocaeli, Turkey, 16Istanbul University, Istanbul, Turkey, 17Division of Rheumatology, Medical School, Ege University, Izmir, Turkey, 18Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, 19Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Conventional disease-modifying anti-rheumatic drugs (cDMARDs) are recommended in addition to glucocorticoids (GC) for all active Takayasu's arteritis (TAK) patients as the first-line therapy. However,…
  • Abstract Number: 1569 • ACR Convergence 2023

    Efficacy and Safety of Tofacitinib and Tocilizumab in 84 Patients with Takayasu Arteritis: Single-Center Post-Hoc Analysis of a Prospective Study

    Jing Li1, Yang Zhao2, Yang Yu3, Xianan Jian4, Yanhong Wang5, yunjiao yang6, Xinping Tian7, Mengtao Li7 and Xiaofeng Zeng7, 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, 2Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China, 3The Affiliated Hospital of Inner Mongolia Medical University, Huhhot, China, 4Puyang Oilfield General Hospital, Puyang, China, 5Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 6Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, 7Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: To compare the efficacy and safety of tofacitinib and tocilizumab in patients with Takayasu arteritis (TAK) in real world situation. Methods: A post-hoc analysis…
  • Abstract Number: 1570 • ACR Convergence 2023

    Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study

    Emma Rinaldi1, Corrado Campochiaro2, Roberto Padoan3, Chengappa Kavadichanda4, Augustine Jose4, Kritika Singh5, Luca Iorio3, Naomi Viapiana6, Upendra Rathore5, Elena Marina Baldissera6, Vikas Agarwal5, Lorenzo Dagna7, Durga P Misra5 and Alessandro Tomelleri8, 1Vita-Salute San Raffaele University, Milan, Italy, 2IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, 3Department of Medicine DIMED, University of Padova, Padova, Italy, 4Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 5Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 6IRCCS San Raffaele Hospital, Milan, Italy, 7Ospedale San Raffaele, Milano, Italy, 8Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy

    Background/Purpose: The 2022 ACR/EULAR classification criteria for Takayasu arteritis (TAK) rely on a point-based clinical and imaging scoring system (from 0 to 22). The aim…
  • Abstract Number: 1571 • ACR Convergence 2023

    Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis

    Nurul Aulia Zakaria1, Andrew Porter2, Robert Maughan2, Charis Pericleous2, Japna Satara3, Matthew Colquhoun4, Priyanka Agrawal3, jan Nouza3, Harold Wilson-Morkeh3, Taryn Youngstein2 and Justin Mason2, 1National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, 2National Heart & Lung Institute, Imperial College London, London, United Kingdom, 3Rheumatology, Hammersmith Hospital, London, United Kingdom, 4Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom

    Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
  • Abstract Number: 1573 • ACR Convergence 2023

    Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020

    Husam el Sharu1, Sukhvir Singh1, Omar Alwahadneh2, Mohammad Alqaisieh3 and Laksmi Subramanian1, 1East Carolina University, Greenville, NC, 2Carle Foundation Hospital, Urbana, IL, 3Hamilton Medical Center, Dalton, GA

    Background/Purpose: Takayasu’s Arteritis (TAK) is a granulomatous large-vessel vasculitis that affects the aorta and its branches, and it is more commonly observed in women. We…
  • Abstract Number: 0215 • ACR Convergence 2023

    Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort

    Erika Biegelmeyer1, Mariana Freitas de Aguiar1, Priscila Dias Cardoso Ribeiro1, Ketty Lysie Libardi Lira Machado2, Maria da Penha Gomes Gouveia2, Camila Maria Paiva França Telles3, Samuel Elias Basualto Dias3, Natália Sarzi Sartori4, Thaís Evelyn Karnopp5, Vanessa de Oliveira Magalhães1, Flávia Maria Matos Melo Campos Peixoto1, Laiza Hombre Dias2, Débora Marques Veghini2, Rodrigo Vieira de Rezende6, Katia Lino Baptista6, Ana Karla Guedes de Melo7, Vitor Alves Cruz8, Maria Cecília Dias Corrêa9, Adriana Maria Kakehasi10, Rejane Maria Rodrigues de Abreu Vieira11, Valderilio Feijó Azevedo12, Olindo Assis Martins-Filho13, Charlles Heldan de Moura Castro1, Ricardo Xavier14, Andréa Teixeira-Carvalho13, Viviane Angelina de Souza9, Odirlei André Monticelo15, Marcelo Pinheiro16, Edgard Torres dos Reis Neto1, Emilia Sato1, Gilda Ferreira17, Gecilmara Pileggi18, Valeria Valim19 and Alexandre wagner Silva de Souza20, 1Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, 2Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES), Vitória, Brazil, 3Universidade Federal do Amazonas, Manaus, Brazil, 4Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 5Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 6Universidade Federal Fluminense, Niterói, Brazil, 7Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil, 8Universidade Federal de Goiás, Goiânia, Brazil, 9Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil, 10Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 11Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil, 12Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, 13Instituto Renè Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Brazil, 14Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 15Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 16UNIFESP/ EPM, São Paulo, Brazil, 17Federal University of Minas Gerais, Belo Horizonte, Brazil, 18UNIFESP, Ribeirão Preto, Brazil, 19Universidade Federal do Espírito Santo, Vitória, Brazil, 20Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil

    Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…
  • Abstract Number: 1574 • ACR Convergence 2023

    The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis

    Sahil Jain1, Abdulrahman Khormi2, Marcela Munoz-Urbano3, Shirish Sangle1 and David D'Cruz4, 1Louise Coote Lupus Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, 2Prince Sattam University Medical College, Al-Kharj, Saudi Arabia, 3Clínica Imbanaco, Cali, Colombia, 4Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom

    Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis which primarily affects the aorta and its main branches. Accurate assessment of disease activity has always been…
  • Abstract Number: 0695 • ACR Convergence 2023

    Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study

    Sabahat Usmani1, Yanint Raksadawan1, Amro Taha1, Harigopal Sandhyavenu1, Jalpan Patel1, Thatiana Schulze Goni1, Hafiz Muhammad Waqar Younas1 and Irisha Badu2, 1Weiss Memorial Hospital, Chicago, IL, 2Onslow Memorial Hospital, Jacksonville, FL

    Background/Purpose: Atrial fibrillation is the most commonly treated cardiac arrhythmia, associated with significant morbidity and mortality. Recent research is suggestive that autoimmunity and inflammation might…
  • Abstract Number: 1575 • ACR Convergence 2023

    Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study

    Darpan Radheshyam Thakare, Upendra Rathore, Kritika Singh, Vikas Agarwal and Durga P Misra, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

    Background/Purpose: Few studies have assessed patient-reported outcome measures in Takayasu arteritis (TAK), a rare large vessel vasculitis. We prospectively analysed fatigue and fibromyalgia in TAK…
  • Abstract Number: 0696 • ACR Convergence 2023

    Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study

    Francois Maillet1, Yann Nguyen2, Olivier Espitia3, Laurent Perard4, Carlo Salvarani5, Etienne Rivière6, Cécile-Audrey Durel7, Philippe GUILPAIN8, Luc Mouthon9, Anna Kernder10, Javier Loricera11, Pascal Cohen12, Isabelle Melki13, Claire De Moreuil14, Nicolas Limal15, Arsène Mekinian16, Nathalie Costedoat-Chalumeau17, Nathalie Morel12, Jonathan Boutemy18, Loic Raffray19, Jean-Sébastien Allain20, Valerie Devauchelle21, Isabelle Kone-Paut22, Marc Fabre23, Marie Durel24, Antoine Dossier25, Sébastien Abad26, Marcella Visentini27, Adrien Bigot28, Halil Yildiz29, Olivier Fain30, Maxime Samson31, Guillaume Gondran32, Vered Abitbol1 and Benjamin Terrier33, 1Cochin Hospital, Paris, France, 2Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, 3CHU de Nantes, Nantes, France, 4CH Saint Hoseph Saint Luc, Lyon, France, 5Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, 6CHU Bordeaux, Bordeaux, France, 7CHU Lyon, Lyon, France, 8University of Montpellier, Montpellier, France, 9Hopital Cochin - Paris University, Paris, France, 10HHU Düsseldorf, Düsseldorf, Germany, 11Hospital Universitario Marqués de Valdecilla, Santander, Spain, 12CHU Cochin, Paris, France, 13Hopital Robert Debré, Sérurier, France, 14CHU de Brest, Brest, France, 15AP-HP, Créteil, France, 16Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, 17Inserm DR Paris 5, Paris, France, 18CHU de Caen, Caen, France, 19CHU la Réunion, La Réunion, France, 20CHU Rennes, Rennes, France, 21UBO, Brest, France, 22Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, 23CH Bourgoin-Jallieu, Bourgoin-Jallieu, France, 24CH Metz, Metz, France, 25AP-HP, Paris, France, 26Avicenne Hospital, Bobigny, France, 27Rome Hospital, Rome, France, 28Tours Hospital, Tours, France, 29Saint Luc Hospital, Bruxelles, Belgium, 30Hopital SAINT ANTOINE APHP, Paris, France, 31Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 32Limoges Hospital, Limoges, France, 33Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: The association of large vessel vasculitis (LVV), whether Takayasu arteritis (TA) or giant cell arteritis (GCA), with inflammatory bowel disease (IBD) is a rare…
  • Abstract Number: 1576 • ACR Convergence 2023

    Application of the 2022 ACR/EULAR Criteria for Takayasu Arteritis to Previously Diagnosed Patients Based on the 1990 ACR Criteria

    Jang Woo Ha1, Sung Soo Ahn2, Jason Jungsik Song2, Yong-Beom Park2 and Sang-Won Lee3, 1Yonsei University College of Medicine, Seodaemun-gu, Seoul, South Korea, 2Yonsei University College of Medicine, Seoul, South Korea, 3Yonsei University College of Medicine, Seoul, South Korea

    Background/Purpose: Recently, a joint group of the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) proposed new criteria for…
  • Abstract Number: 0697 • ACR Convergence 2023

    Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis

    Adam Mayer1, Weiming Hu2, Kyle Bittinger2, Rui Liang3, Naomi Amudala3, Shubhasree Banerjee3, Peter Merkel3 and Rennie Rhee3, 1University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The gut microbiome has a critical role in immune homeostasis and there is growing interest in understanding the relationship between the microbiome and autoimmunity.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology